The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide

Oncology Research

Volumn 18, Issue 11-12, 2010, Pages 601-605

  Rozados, Viviana R ^a   Mainetti, Leandro E ^a   Rico, María J ^a   Zacarías Fluck, Mariano F ^a   Matar, Pablo ^a,b   Scharovsky, O Graciela ^a,c  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Cyclophosphamide; Immune response; Lymphoma; Metronomic chemotherapy

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; INTERLEUKIN 10;

ANIMAL; BLOOD; FEMALE; IMMUNOLOGY; LYMPHOMA; MOUSE; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; FEMALE; INTERLEUKIN-10; LYMPHOMA; MICE; RATS;

EID: 77956898655     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12777678141662     Document Type: Article

References (19)

1. Kerbel, R. S.; Kamen, B. A. The anti-angiogenic basis of immetronomic chemotherapy. Nat. Rev. Cancer 4:423-436; 2004.
2. Matar, P.; Celoria, G.; Font, M. T.; Scharovsky, O. G. Antimetastatic effect of a single-low dose of cyclophosphamide on a rat lymphoma. J. Exp. Clin. Cancer Res. 14: 59-63; 1995.
3. Matar, P.; Rozados, V. R.; Roggero, E. A.; Bonfil, R. D.; Scharovsky, O. G. Modulation of the antimetastatic response against a rat lymphoma by a single-low dose of cyclophosphamide. Tumour Biol. 19:69-76; 1998.
4. Matar, P.; Rozados, V. R.; González, A. D.; Dlugovitzky, D. G.; Bonfil, R. D.; Scharovsky, O. G. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur. J. Cancer 36:1060-1066; 2000. (Pubitemid 30316433)
5. Matar, P.; Rozados, V. R.; Gervasoni, S. I.; Scharovsky, O. G. Down regulation of T-cell derived IL-10 production by low-dose cyclophosphamide treatment in tumour-bearing rats restores in vitro normal lymphoproliferative response. Int. Immunopharmacol. 1:307-319; 2001.
6. Matar, P.; Rozados, V. R.; Gervasoni, S. I.; Scharovsky, O. G. Th2/Th1 switch induced by a single-low dose cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol. Immunother. 50:588-596; 2002.
7. Rozados, V. R.; Sánchez, A. M.; Gervasoni, S. I.; Berra, H. H.; Matar, P.; Scharovsky, O. G. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression and is devoid of toxicity. Ann. Oncol. 15:1543-1550; 2004.
8. Folkman, J. Endogenous angiogenesis inhibitors. APMIS 112:496-507; 2004.
9. Bocci, G.; Falcone, A.; Fioravanti, A.; Orlandi, P.; Di Paolo, A.; Fanelli, G.; Viacava, P.; Naccarato, A. G.; Kerbel, R. S.; Danesi, R.; Del Tacca, M.; Allegrini, G. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br. J. Cancer 98:1619-1629; 2008.
10. Calderari, S.; Font, M. T.; Garrocq, O.; Martinez, S.; Morini, J. C.; Puche, R.; Tarrés, M. C. The inbred IIM/Fm stock. Rat News Lett. 25:28-29; 1991.
11. Celoria, G. C.; Hinrichsen, L. I.; Font, M. T. Tumour behaviour of lymphoma TACB in rats resistant or susceptible to Sarcoma E-100. Com. Biol. (Bs Aires) 5:73-84; 1986.
12. Kerbel, R. S. Antiangiogenic therapy: A universal chemo-sensitization strategy for cancer? Science 312:1171-1175; 2006.
13. Browder, T.; Butterfield, C. E.; Kraling, B. M.; Shi, B.; Marshall, B.; O'Reilly, M. S.; Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:1878-1886; 2000.
14. Berd, D.; Mastrangelo, M. J. Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 48:1671-1675; 1988.
15. Brode, S.; Cooke, A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit. Rev. Immunol. 28:109-126; 2008.
16. Rozados, V. R.; Mainetti, L. E.; Rico, M. J.; Zacarías Fluck, M. F.; Matar, P.; Scharovsky, O. G. Antiangiogenic and immunomodulatory effect of the metronomic therapy with cyclophosphamide (Cy). Biocell 31:119; 2007.
17. Rico, M. J.; Zacarías Fluck, M. F.; Giordano, R.; Scharovsky, O. G. Low dose cyclophosphamide (Cy) treatment induces a decrease in the percentage of regulatory T cells in lymphoma-bearing rats. Proc. Am. Assoc. Cancer Res. 48:233; 2007.
18. Ghiringhelli, F.; Menard, C.; Puig, P. E.; Ladoire, S.; Roux, S.; Martin, F.; Solary, E.; Le Cesne, A.; Zitvogel, L.; Chauffert, B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56:641-648; 2007.
19. Sung, C. C.; Chang, P. Y.; Cheng, M. F.; Sheu, L. F.; Yao, N. S. Successful metronomic low-dose cyclophosphamide therapy in an older patient with advanced mucosa-associated lymphoid tissue lymphoma. Ann. Hematol. 88:1257-1259; 2009.